Clinical trial
A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1
NCT00306631 · CASI Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00306631 |
|---|---|
| Title | A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1 |
| Official title | A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Advanced or Metastatic Breast Cancer |
| Lead sponsor | CASI Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | MKC-1 |
| Enrollment | 65 |
| Start date | Jan 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Mar 24, 2006 |
| Last update posted | Jun 3, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: